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Abstract 
Context: The International Society of Nephrology (ISN) has adopted a proactive 
approach to defining the current state of kidney care and the unmet needs through a 
multifaceted ‘Closing the Gaps’ initiative. As part of this initiative, the ISN convened a 
meeting of experts to develop an approach to tackling acute kidney injury (AKI) and 
chronic kidney disease (CKD). This manuscript expands on the recently published ISN 
CKD Roadmap and reports on the discussions of the Working Group assigned the task 
of reviewing the global impact of complication of chronic kidney disease. The Working 
Group defined the following goals: 
 
Goal 1: Optimise the management of anaemia, endocrine and metabolic 
abnormalities associated with CKD. The impact of these conditions at a global level 
is not well understood, particularly in regions where renal replacement therapy is not 
readily available. Some treatment regimens may be affordable in low to middle income 
countries (LMICs) and if implemented, could have an impact on the burden of suffering 
associated with CKD.  
 
Goal 2: Improve prevention and management of cardiovascular complications 
linked to CKD. Most research into cardiovascular complications of CKD has focused on 
atherosclerotic disease (myocardial infarction, ischaemic stroke and peripheral 
gangrene). There has been growing recognition that other forms of cardiovascular 
disease (CVD) such as heart failure, valvular disease and arrhythmias, have a major 
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impact on patient outcomes. Much less in known about the mechanisms and treatment 
of these “non-atherosclerotic” complications. 
 
Goal 3: Improve the diagnosis and management of symptoms associated with 
CKD. 
Symptom management is one of the greatest challenges in the management of CKD 
with limited knowledge about the mechanisms associated with the development of these 
common problems, and how best to characterise them into usable clinical phenotypes.  
 
Conclusions: Improved understanding of the complications of CKD may alleviate 
suffering and may prolong life among the millions of people worldwide both in 
developed countries and in regions where renal replacement therapy is not widely 
available.    
 
Key words: CKD, complications, mechanisms, management, knowledge gaps  
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Introduction 
Chronic kidney disease (CKD) is associated with several adverse clinical outcomes 
such as cardiovascular events, kidney failure requiring renal replacement therapy 
(RRT), mortality, and for survivors, poor quality of life in general.1-6 Kidney disease 
amplifies the enormous burden and the population health impact associated with both 
communicable and non-communicable diseases (NCDs)6,7.  
 
CKD has not been included in the major chronic disease control strategies at 
international, regional and/or national levels. The progressive nature of CKD, the 
associated cardiovascular morbidity and mortality, and the ensuing end-stage kidney 
disease (ESKD) place a considerable burden on global healthcare resources6-8. A better 
understanding of the nature of the complications associated with CKD could help to 
optimise diagnosis, prevention and management. 
 
The International Society of Nephrology (ISN) ‘Closing the Gaps’ initiative has been set 
up to define the global needs and current state of kidney care building on some of the 
AKI initiatives (0by25; www.theisn.org) and focussing on CKD. The goal is to create a 
‘blueprint’ to enhance optimal care globally, through research, education and advocacy. 
As part of this initiative, the ISN convened the first Global Kidney Health Summit, July 
26-28, 2016 in Vancouver, Canada. This article expands on the recently published ISN 
CKD Roadmap,9 which is the output from the Summit. 
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CKD-related complications: Current state 
Progressive CKD is linked to several complications with higher prevalence and intensity 
at lower levels of kidney function and which interact with each other8,10-11 (Table 1, 
Figure 1 & 2). These complications contribute to high morbidity, mortality and poor 
quality of life. Some of these complications can be readily defined and quantified 
(cardiovascular disease, hypertension, anaemia, mineral bone disorder, volume 
overload, electrolytes and acid-base abnormalities) and may require a specific 
management approach, for example the prescription of erythropoiesis stimulating 
agents to correct anaemia. Other complications are less well defined and may be 
manifest as the complex symptoms often associated with advanced CKD which have a 
less distinct pathogenesis such as anorexia, fatigue, cachexia, pruritus, nausea and 
sexual dysfunction. The work group identified the following complications of CKD as 
being relevant to the global burden of poor health caused by CKD: 
 
1. Hypertension: Hypertension remains one of the most damaging complications of 
CKD and is thought to contribute both to acceleration of progressive decline in kidney 
function and to CVD and related mortality. Both detection and control of high blood 
pressure is frequently suboptimal and improvements could directly help patients.12 
The Systolic Blood Pressure Intervention Trial (SPRINT) provided important 
information about the effects of more stringent lowering of systolic blood pressure to 
a target of <120 mmHg that may be relevant to CKD patients although this trial 
excluded high risk subjects with CKD and proteinuria or diabetes.13 Lifestyle 
modifications such as weight loss and dietary salt restriction may also improve 
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blood pressure control. Such interventions can be lower in cost than 
pharmacological therapy, and have the potential to impact on outcomes such as 
heart failure and stroke in both developed healthcare systems and low and middle 
income countries (LMICs). Since many anti-hypertensive agents are available and 
affordable in LMICs, one feasible goal would be to improve control of high blood 
pressure complicating CKD aiming to achieve target ranges in a proportion of 
patients. Such a goal could be attainable globally and the impact easily measurable. 
 
2. Cardiovascular complications: Cardiovascular diseases represents the leading 
cause of mortality in patients with CKD and the prevalence and burden of these 
complications increases with declining kidney function (Figure 1 & 2).8,14 For 
example, the risk of mortality from cardiovascular disease is 8.1-fold greater in a 
patient with CKD stage G5 A3 (eGFR <15 ml/min/1.73msq, urinary 
albumin:creatinine ratio > 300 mg/g) when compared to a to a reference population 
without kidney disease.4 While the risk of conventional atherosclerotic cardiovascular 
events increases with CKD, the majority of the increase in risk is attributable to “non-
atherosclerotic” pathologies such as left ventricular hypertrophy with diastolic and 
systolic dysfunction, valvular disease and arterial calcification. These pathologies 
may manifest as atrial and ventricular dysrhythmias, heart failure and sudden death.15 
While it is generally accepted that treatment of traditional cardiovascular risk factors 
such as cholesterol16 and blood pressure17 is efficacious in the CKD population, 
particularly in patients with stages 1-3 CKD, there are additional risk factors to 
consider in CKD patients, most of which are considered to be CKD complications. For 
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example, mineral and endocrine disturbances that characterise the CKD-mineral 
bone disorder, such as phosphate retention, elevated levels of fibroblast growth 
factor 23 and disturbances in Klotho metabolism may contribute to cardiomyopathy 
and vasculopathy.18 Improvements in our understanding of the factors that contribute 
to CKD-associated cardiovascular disease and identification of additional therapeutic 
targets, along with efforts to control blood pressure and increase prescription of lipid-
lowering therapies, could ultimately lead a global reduction in the burden of 
cardiovascular disease attributable to CKD.19 
 
3. Anaemia: Anaemia complicating CKD has been well characterised and is treated in 
many parts of the world with iron and erythropoiesis-stimulating agents (ESAs). 
However, the optimal doses of ESAs, and indications and dosage of parenteral iron 
are not established. While ESAs can provide symptomatic relief, the impact of these 
medications on survival remains unclear20 and may increase cardiovascular and 
cancer risks. The full spectrum of side effects of ESA are not known nor has the role 
of high hepcidin in CKD been adequately studied.21 There may be regional 
differences in resistance to ESA therapy, which renders patient more susceptible to 
the harmful effects of these high cost agents.22 The current management of anaemia 
of CKD in many LMICs where ESAs are variably available and prohibitively 
expensive is different from developed countries where these agents are widely 
available. While we still need to learn more about the risks and benefits of ESAs and 
intravenous iron, efforts to make these therapies (and blood transfusions) more 
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readily accessible in LMICs may help to reduce the symptom burden associated with 
anaemia complicating CKD.  
 
4. CKD-related mineral bone disorder: The syndrome of chronic kidney disease-
mineral and bone disorder (CKD-MBD) was defined by KDIGO23-25 and encompasses 
traditional mineral biochemical abnormalities, the spectrum of renal osteodystrophy, 
and soft tissue calcification. Left ventricular hypertrophy may be causally linked to 
these abnormalities. This complex group of disorders are poorly understood and 
despite a considerable body of preclinical data, very few developments have been 
translated to clinical applications.10 High blood phosphate levels, deficiency of vitamin 
D and secondary hyperparathyroidism can be monitored and treated although the 
true benefits of interventions to correct these abnormalities are unproven. The role of 
low cost calcium-based phosphate binders is controversial because of the potential 
for these agents to exacerbate tissue calcium deposition.26,27 A pragmatic approach 
based on our current level of knowledge would be to increase availability of 
phosphate binders, nutritional vitamin D and analogues of 1,25 dihydroxy vitamin D to 
alleviate the recognised symptoms that result from tertiary hyperparathyroidism.   
 
5. Salt and water retention: In CKD stages 4-5 and possibly in stage 3 there is loss of 
defense against both sodium excess and sodium depletion. In clinical practice, 
sodium excess with fluid retention is by far the more common, although the exact 
prevalence has not been determined. While extracellular fluid volume may be 
expanded, sodium balance appears to be relatively well maintained until ESRD.28 
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Excess sodium and fluid not only contribute to oedema, which may negatively impact 
on quality of life, but also to hypertension and thereby to cardiovascular disease, 
(specifically concentric left ventricular hypertrophy which can result in diastolic 
dysfunction). The mainstay of therapy is adherence to simple fluid balance (“intake vs 
output”) concepts, restriction of dietary salt intake and use of natriuretic agents (which 
may be less effective in the more advanced stages of CKD). Thiazides and loop 
diuretics are widely available at low cost and could be used more widely to alleviate 
symptomatic oedema in CKD patients with the potential to improve cardiovascular 
outcomes. 
 
6. Metabolic acidosis and electrolytes disorders: Metabolic acidosis is common in 
CKD and is caused when acid intake and generation exceed renal acid excretion. In 
the early stages, it may be manifest as “acid excess with normal bicarbonate” a state 
of positive acid balance without low plasma bicarbonate due to buffering and renal 
adaptation.29 Alkali therapy is effective but limited by the mandatory sodium and/or 
potassium loads. Chronic metabolic acidosis contributes to skeletal muscle 
catabolism, insensitivity to endocrine hormones and bone disease30 and may 
accelerate progression of CKD.31 The challenge is early detection which requires 
identification of potentially harmful acid loading before a fall in serum bicarbonate 
occurs. Treatment of metabolic acidosis could be implemented on a global basis 
since the therapies are inexpensive, but the benefits of such intervention are 
unproven and the sodium or potassium loading that accompanies current alkali 
therapy may be harmful, particularly in more advanced stages of CKD. Alternative 
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ways of alkali delivery are needed. Non-sodium and potassium containing alkali are 
under development but availability and affordability, particularly to LMIC, are likely to 
be problematic. At the present time, more widespread use of sodium bicarbonate to 
treat symptomatic metabolic acidosis in advanced CKD seems appropriate in an 
effort to alleviate suffering. 
 
7. Uremic symptoms: The syndrome of “uremia” encompasses a variety of symptoms 
including anorexia, fatigue, cachexia, pruritus, nausea, restless leg syndrome, sleep 
disturbances, and sexual dysfunction.32 Pruritus is common and can adversely impact 
on quality of life. The causes are poorly understood but are likely to include the 
accumulation of specific “uremic toxins” in the skin. Distinguishing “uremic itching” 
from itching caused by other conditions is important as management may be 
different. Topical therapy and antihistamines are accessible to LMIC. Other agents 
such as gabapentin and opioid receptor modulators are likely to be of more limited 
availabity.33 The treatment of hyperparathyroidism and hyperphosphatemia may be 
effective in relieving pruritus in at least some patients. Restless leg syndrome is a 
related clinical diagnosis that can be debilitating.23 Although this problem is 
recognised in individuals with normal kidney function, it is much more prevalence in 
CKD and dialysis patients. Both pruritus and restless leg syndrome are associated 
with sleep disturbance, depression, poor quality of life, higher cardiovascular 
morbidity and higher mortality. The pathophysiology is unknown but may reflect a 
state of general poor health. The symptoms of restless leg syndrome can be relieved 
by exercise as well as by several pharmacologic agents including gabapentin, 
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dopaminergic modulators, serotonin antidepressants, and lithium. Although data on 
efficacy of these interventions is limited they are accessible in many LMICs. 
 
Knowledge gaps 
Research into CKD complications over the last few decades has been largely focused 
on the management of endocrinological abnormalities (anaemia and secondary 
hyperparathyroidism). Despite this effort there have been few clinical advances proven 
to improve clinical outcomes. This calls for more efforts to improve our understanding of 
the mechanisms by which these abnormalities impact on patient-related outcomes, the 
clinical implications of the complications and the development of more effective 
treatment strategies (Panel 1).  
 
The limitations in our knowledge reflect the variety and complexity of the underlying 
pathophysiology processes that lead to CKD complications and the heterogeneity in 
their presentation. This is reflected in the limited therapeutic options available. 
Unfortunately, the “uremic symptoms” described above, which matter most to patients 
are the most poorly understood of all CKD complications.32 
 
Of the other CKD complications, cardiovascular disease is the perhaps the most 
important because of the potential to limit length and quality of life. However, as 
discussed above, the pathogenetic mechanisms may be somewhat different in CKD as 
compared to the general population, with pathways that are complex involve and may 
involve other CKD-related complications. While the pathophysiology of cardiovascular 
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disease remains incompletely understood, it will be challenging to develop effective 
treatment strategies with a high degree of specificity. 
 
The work group defined the following specific goals to focus future efforts to alleviate 
morbidity and mortality resulting from CKD complications at a global level.  
 
Goal 1: Optimise the management of anaemia and other endocrine abnormalities 
associated with CKD. Clinical practice guidelines such as those developed by Kidney 
Disease: Improving Global Outcomes (KDIGO) provide recommendations on the 
approach to the management of these common complications associated with CKD.24,25 
The clinical consequences of these complications in LMICs, particularly in regions 
where renal replacement therapy programmes are not available, needs to be defined. 
Dissemination and implementation of KDIGO guidelines in LMICs has been limited and 
could be improved.34 
 
To achieve this goal and close these gaps the following activities were suggested: 
 
Activity 1: Promote research into understanding the links between laboratory 
abnormalities (low hemoglobin, mineral disorders such as calcium and 
phosphate and elevated PTH) and clinically relevant outcomes (CVD outcomes, 
progression of CKD, and uremic symptoms. 
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Activity 2: Promote consistent assessment and documentation of laboratory 
abnormalities in CKD populations as recommended in KDIGO guidelines in both 
developing and developed nations of the world. 
 
Activity 3: Promote research and education into region-specific causes of 
abnormalities in CKD patients. Most publications focussed on the management of 
laboratory abnormalities in CKD populations are based on studies conducted in 
developed countries.11,35-37 However, it is likely that the underlying causes of these 
abnormalities differ by health system characteristics and are influenced by socio-cultural 
factors. For example, in LMICs, parasitic infection or nutritional deficiency may be more 
common causes of anemia than erythropoietin deficiency and are not appropriately 
treated with ESAs.   
 
Activity 4: Promote availability of affordable point-of-care measurement devices 
and treatments for endocrine, abnormalities. The key challenge is the lack of 
adequate laboratory capacity and/or trained workforce to measure the common 
biochemical abnormalities (e.g. PTH) due to issues with cost and available of reagents. 
Effort should be targeted towards development affordable point-of-care testing 
instruments for these common laboratory abnormalities. Point-of-care devices with 
acceptable performance at affordable prices should be a high priority for future research 
and perhaps public-private partnerships. Data from a variety of settings that document 
the current availability of affordable assays (or lack thereof) would help to make the 
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case that these innovations are worthwhile, and should be included in future global CKD 
surveys. 
 
Goal 2: Improve prevention and management of cardiovascular complications 
linked to CKD. Most cardiovascular research in CKD has focused on atherosclerotic 
disease. Non-atherosclerotic diseases that may, for example, lead to heart failure and 
sudden death through arrhythmia have been less well studied. Understanding regional 
variations in CVD phenotype among CKD populations may offer new insights into how 
outcomes can be improved. In addition, much remains to be learned about fundamental 
aspects of cardiovascular risk reduction in CKD populations (e.g., optimal target blood 
pressure or benefits of aspirin in dialysis patients). Finally, continued work is needed to 
develop novel therapies for CKD-related cardiovascular disease. 
 
Activity 1: Develop an integrated research program to better understand non-
traditional cardiovascular risk factors and impact on patients’ outcomes in terms 
mechanism, treatment and prognosis. The current approach to CVD management 
largely involves extrapolation of evidence from the general population. There is an 
pressing need for focused research programs that evaluate the benefits of standard 
treatment approaches (e.g., ARB for heart failure, implantable defibrillators to prevent 
sudden cardiac death) in CKD populations, as well as investigate novel interventions 
that might reduce the risk of cardiovascular events in people with kidney disease (e.g., 
intradialytic potassium profiling). 
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Activity 2: Improve understanding of global variation in cardiovascular diseases 
associated with CKD. The phenotype of cardiovascular diseases in people with CKD 
exhibits potentially important regional variation. For example, Japanese haemodialysis 
patients appear to have a lower risk of sudden death than those in other countries. 
Whether this is due to patient characteristics, environmental factors or treatment 
practices is unknown. If this observation is confirmed, further study of between-country 
variations in risk and outcomes might lead to new insights into pathophysiology or 
optimal management. Careful observational studies that use common definitions to 
compare the epidemiology of these conditions across countries should be a high 
priority. There is also paucity of data from LMICs on cardiovascular disease outcomes 
in patients with CKD, and there are pertinent geographic and racial characteristics that 
define these disorders in the populations from those countries.  
 
Activity 3: Determine barriers to dissemination and implementation of existing 
guidelines on dyslipidemia and hypertension management to reduce 
cardiovascular risk in CKD, and implement strategies to overcome those barriers. 
Although new research is certainly needed, knowledge translation (rather than 
knowledge generation) should be the key priority in other areas. For instance, there is 
little controversy about the merits of controlling blood pressure, blood sugar and 
dyslipidemia in people with less advanced CKD, yet many people worldwide do not 
have access to these treatments. Knowledge transfer and advocacy efforts should focus 
on the implementation of global guidelines in CKD populations, especially in LMIC. 
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Activity 4: Develop new therapeutic approaches to reduce cardiovascular disease 
risk in CKD patients. In addition to a high burden of traditional risk factors, 
cardiovascular disease in CKD appears to also be driven by novel (CKD-specific) risk 
factors. For example, abnormalities in phosphate, fibroblast growth factor 23 and Klotho 
all appear to contribute to cardiovascular in CKD populations. Continued work is needed 
to translate discoveries from biomedical science into novel therapies that address these 
risk factors and mitigate the burden of CVD. 
 
Activity 5: Promote further research into optimal therapeutic targets for 
cardiovascular risk factor management (e.g., blood pressure control) and how 
best to achieve them. Key knowledge gaps exist in fundamental aspects of 
cardiovascular management and prevention in CKD populations, especially in dialysis 
patients. Clinical trials are needed to examine the risks and benefits of treatments like 
aspirin, renin/angiotensin system interruption and spironolactone in patients with 
advanced kidney disease and kidney failure. Since these trials are unlikely to be funded 
by industry partners, their success likely depends on cooperation between public 
research funders from different countries. 
 
 
Goal 3: Improve the diagnosis and management of symptoms associated with 
CKD. 
These present the greatest challenge in the management of CKD related complications 
stemming from limited knowledge about the mechanisms associated with the 
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development of these common problems and how best to characterise them into usable 
clinical phenotypes. The Nephrology research community should focus on 
understanding these common but often neglected complications that may matter most 
to CKD patients.  
 
Activity 1: Develop a taxonomy of symptoms (clinical phenotypes) associated 
with CKD and their impact on quality of life and functional status. The clinical and 
epidemiologic characteristics associated with the presence, severity, onset, and 
remission of CKD-related symptoms are poorly described. How symptoms (individually 
and collectively) impact on quality of life and other patient-important outcomes such as 
employability and functional status has not been completely studied. In addition, the 
relative importance of each symptom to the total symptom burden is not quantified. This 
information is required to characterize the impact of symptoms on patient well-being 
(thus building the case for action) and to identify the symptoms and patient populations 
that should be the highest priority for immediate study. 
 
Activity 2: Enhance understanding of the pathophysiology and mechanistic 
pathways of the key symptoms to guide diagnostic, prognostic and therapeutic 
decisions. Because the mechanisms underlying uremic symptoms are poorly 
understood, no specific treatments are available. Multidisciplinary research efforts 
should capitalize on new technologies such as metabolomics and proteomics to link 
uremic toxins with symptoms and to identify the pathophysiology that causes or 
exacerbates symptom burden. Consideration should be given to study of potentially 
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related symptoms (e.g., pain and pruritus, which have similar neurobiology). 
Collaboration of scientists from multiple disciplines, communication with patients and 
communication with industry partners may help to ensure maximum potential for clinical 
impact and facilitate commercialization. 
 
Activity 3: Building and enhancing effective symptoms management strategies. 
Regulatory authorities have approved few if any drugs for the treatment of uremic 
symptoms and there often is very little evidence to support off-label use of therapies 
although this is common. Summarizing what is known about available therapies and 
evaluating the best candidates in well-designed clinical trials should be a high priority. 
This could include therapies for similar symptoms associated with other conditions (e.g., 
chemotherapy-associated nausea) as well as therapies targeted at uremic-specific 
conditions (e.g., phototherapy for pruritus). Depending on the findings of Activity 2, new 
candidate treatments could undergo clinical trials. 
 
Conclusion 
Progressive CKD is linked to several complications with higher frequency and greater 
severity in the advancing stages of the disease. These complications lead to high 
morbidity, mortality and poor quality of life. We have outlined three key goals 
(underpinning a set of activities) targeted at reducing the population health impact of 
CKD-related complications. Although there has been considerable progress in defining 
CKD-related complications across regions and countries, significant gaps in knowledge 
still exist and optimal ways to specifically close these gaps remained undefined. This is 
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the first attempt to develop a blueprint for a concerted approach to better understand 
these disorders. This involves improving our understanding of the spectrum of 
pathophysiology and mechanistic pathways, clinical presentations and phenotypes, as 
well as the development of practice and policy guidelines to guide optimal care. Under 
this ISN initiative, we have developed an action plan to enhance our understanding of 
which uremic symptoms impact most on quality of life in CKD, the cause of these 
symptoms and the best management strategies to alleviate them.  
 
We endeavoured to identify the CKD-related complications with the greatest impact on 
population and/or individual patient survival and quality of life. We identified seven 
systemic complications of CKD, how they evolve and interact with each other in the 
whole CKD spectrum (Table 1, Figure 1 & 2). We then defined the current state of 
knowledge and existing gaps and developed a set of goals, with activities and 
deliverables relevant to each goal. We also defined potential threats and opportunities 
towards achieving such goals (Panel 1). We deliberately focused on three key goals 
that have immediate deliverables and potential for impact at the global level. 
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Table 1. Systematic complications of CKD and cross-links 
 
System Common manifestations 
C
a
rd
io
v
a
s
c
u
la
r E
n
d
o
/m
e
ta
b
o
li
c
 
G
a
s
tr
o
in
te
s
ti
n
a
l 
H
e
m
a
to
lo
g
ic
 
N
e
u
ro
lo
g
ic
 
M
u
s
c
u
s
k
e
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te
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u
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e
n
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Cardiovascular Atherosclerosis, HTN, 
cardiomyopathy 
 X  X X   
Endo/metabolic Menstrual disorders, sexual 
dysfunction, infertility, pregnancy 
disorders, electrolytes, and MBD 
X  X X X  X 
Gastrointestinal Anorexia, nausea, emesis, weight 
loss 
 X      
Hematologic Anaemia, platelets disorders, 
coagulopathy, low cell count and 
infection risk 
X  X    X 
Neurologic Neuropathy, seizures (with severe 
uremia), strokes 
X X     X 
Musculoskeletal MBD, fractures, myopathy x x   x  x 
Intergument Dry skin, dermatitis, pruritus  X  X X   
Complex 
symptoms* 
Fatigue, insomnia, impotence, 
cachexia 
X X X X X  X 
X denotes crosslink across systems, e.g. MBD contributing to cardiovascular, anaemia 
contributing to cardiovascular, and interplay of all systemic features causing complex 
symptoms phenotypes. HTN =hypertension. MBD=mineral bone disorder. 
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Panel 1. Action plan towards reducing the global impact of CKD-related complications9 
Goal and related activities Opportunities Threats 
Goal 1: Optimize the 
management of anaemia, 
endocrine and metabolic 
abnormalities associated with 
CKD 
 
 Activity 1: Promote 
research to understand 
links between laboratory 
abnormalities (low 
hemoglobin, mineral 
disorders such as calcium 
and phosphate and 
elevated PTH) and 
clinically outcomes. 
 
 Activity 2: Promote 
consistent assessment and 
documentation of 
laboratory abnormalities in 
CKD populations per 
KDIGO guidelines in both 
developing and developed 
nations of the world. 
 
 Activity 3: Promote 
research and education 
into region-specific causes 
of abnormalities in CKD 
patients. 
 
 Activity 4: Promote 
availability of affordable 
point-of-care measurement 
devices. 
Availability of globally 
accepted KDIGO guidelines. 
 
International collaborative 
networks of clinicians and 
researchers. 
 
International advocacy support 
such as the ISN, and other 
regional and national 
nephrology associations. 
 
Patient advocacy groups and 
kidney foundations 
 
Willing and supportive industry 
partners 
Lack of proven efficacy of the 
current management arsenals 
(e.g. Erythropoietin, vitamin D) 
to impact positively on patient 
outcomes beyond changes in 
laboratory metrics. 
 
Limited access and affordability 
issues of the available 
medications in the developing 
nations. 
 
 
Limited and unavailable 
diagnostic tools across all 
settings. 
 
Language barriers in guidelines 
disseminations (though KDIGO 
making significant efforts to 
eliminate this barrier but 
remains a challenge due to 
multiplicity of languages across 
countries) 
Goal 2: Improve prevention and 
management of CVD-related 
complications linked to CKD 
 
 Activity 1: Integrated 
research program to better 
understand non-traditional 
CVD risk factors and 
impact on patients’ 
outcomes. 
 
 Activity 2: Improve 
understanding of global 
variation in CVD in CKD 
population. 
 
As above 
 
CVD recognition as the most 
common adverse endpoint in 
CKD 
As above 
 
Very limited evidence as care 
approach remains an 
extrapolation based on studies 
in general population 
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 Activity 3: Determine 
barriers to dissemination 
and implementation of 
existing guidelines on CVD 
management. 
 
 Activity 4: Develop new 
therapeutic approaches to 
reduce CVD risk in CKD 
patients. 
 
 Activity 5: Promote further 
research into optimal 
therapeutic targets for CV 
risk factor management. 
Goal 3: Improve the diagnosis 
and management of symptoms 
associated with CKD 
 
 Activity 1: Develop a 
taxonomy of symptoms 
(clinical phenotypes) 
associated with CKD and 
their impact on quality of 
life and functional status. 
 
 Activity 2: Enhance 
understanding of the 
pathophysiology and 
mechanistic pathways of 
the key symptoms to guide 
diagnostic, prognostic and 
therapeutic decisions. 
 
 Activity 3: Building and 
enhancing effective 
symptoms management 
strategies 
 
Growing interests in the 
nephrology community to 
focus research in this area. 
 
Important area of patients’ 
priority with increasing 
attention that gives voice to 
both researchers and their 
funders to develop interest in 
this area. 
Lack of standard taxonomy to 
define disorders. 
 
Significant heterogeneity in 
manifestation of these 
disorders. 
 
Limited fundamental knowledge 
of the disorders in terms of 
pathophysiologic mechanisms. 
 
Change management from 
what the practitioners and 
researchers are accustomed to. 
CKD=chronic kidney disease.  CVD= Cardiovascular disease. KDIGO=Kidney Disease Improving Global 
Outcomes. PTH=parathyroid hormone 
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Figure 1. Progressive CKD and related complications by disease stage 
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Figure 2. CKD-related complications: Cross-links and interactions 
 
 
